Immune Reconstitution in Late-Presenting HIV-Positive a Case with Idiopathic Liver Cirrhosis and Ischemic Brain Stroke

Author:

Pakov Ivaylo N.1

Affiliation:

1. 1 Department of Infectious Diseases, Epidemiology, Parasitology and Tropical Medicine, Faculty of Public Health , Medical University-Pleven , Bulgaria

Abstract

SummaryA patient diagnosed with late-presenting HIV infection [CD4 count 86 cells/mm3, viral load (VL) 95 000 copies RNA/mL], treated with DRV/c 800/150 mg (Rezolsta®) and TDF/FTC 200/245 mg, was hospitalized with ischemic brain stroke, confirmed by CT scan and MRI. Motor functions quickly recovered, but nausea, abdominal heaviness, ascites, and hepatosplenomegaly appeared. Laboratory investigations revealed anaemia, thrombocytopenia, normal transaminases, increased GGT and negative serological tests for HBV and HCV and she was diagnosed with Gastroenterologists diagnosed liver cirrhosis. After 20 days of hospital treatment, the patient recovered from the stroke and ascites but with persisting anaemia and thrombocytopenia. Liver cirrhosis had been confirmed, and relevant treatment had been administered. Six months later, an MRI of the brain revealed an improved image. Follow-up showed stabilized somatic and neurologic status, improved laboratory parameters, stable T-helper count and undetectable viral load (VL). ART regimen continued with Raltegravir 400 mg (Isentress®) 2×1 tablet/24 h, TDF/FTC 200/245 mg 1 tablet/24 h. Three months later, the patient continued her treatment continued abroad. The increased access to precise diagnosis and treatment with improved adherence has transformed the HIV-infection into a manageable chronic health condition, even in complicated cases.

Publisher

Walter de Gruyter GmbH

Subject

General Medicine

Reference22 articles.

1. UNAIDS. Fact sheet – World AIDS Day 2021. [Internet] Available from: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf

2. Samuel K. Getting to 95-95-95: global use of HIV generics would result in large reductions in spending, new infections and deaths. NAM AIDS map 2021 July 9 [Internet] Available from: https://www.aidsmap.com/news/jul-2021/getting-95-95-95-global-use-hiv-generics-would-result-large-reductions-spending-new

3. Heath K, Levi J, Hill A. Reaching UNAIDS 95-95-95 targets worldwide: predicted benefits and treatment costs with generic manufacture. AIDS. 2021;35(2):197-203.

4. Girum T, Wasie A, Worku A. Trend of HIV/AIDS for the last 26 years and predicting achievement of the 90-90-90 HIV prevention targets by 2020 in Ethiopia: a time series analysis. BMC Infect Dis. 2018;18:320.

5. UNAIDS. Global AIDS update 2020. Seizing the moment: tackling entrenched inequalities to end epidemics. 2020. [Internet] Available from: https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3